In conclusion, the add-on of GLP-1 analogue to the intensive insulin therapy with CSII not only significantly showed further effect among glucose control but remarkably potentiated the β- cell function in patients with poorly controlled type 2 diabetes mellitus. The gene discussed is INS; the disease is diabetes mellitus.